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a  b  s  t  r  a  c  t
Introduction: Uveal melanoma is a rare tumour caused by genetic factors and alterations in
the  immune response. Inflammatory bowel disease (IBD) is a multifactorial chronic inflam-
matory disorder characterized by an inappropriate or excessive immune response. The two
main types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). A diagnosis of IBD and
the  use of immunosuppressive drugs are both independently associated with an increased
risk  of developing skin melanoma. The association between IBD and uveal melanoma (UM)
has  not been previously described.
Cases description: Two young Caucasian men, aged 24 and 28, developed UM 3 and 15
years, respectively, after being diagnosed with IBD. Both received long-term treatment with
immunomodulatory drugs, with periodic switching among the drugs due to the refractory
nature of IBD. In both cases, melanoma was treated by brachytherapy with iodine-125 COMS
plaque implant at a dose of 75 Gy.
Discussion: Chronic inflammation can promote cell proliferation and growth. The use of
immunomodulatory drugs is associated with an increased risk of developing melanoma
and  non-melanoma skin cancer. The two patients described in this report both had long-standing IBD treated with immunomodulatory drugs. It seems reasonable to suggest that
these  two factors may have promoted the development of uveal melanoma. More studiesare  warranted to investiga
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Fig. 1 – Ocular ultrasound that highlights the uveal
melanoma in patient no. 1.
Fig. 2 – Ocular ultrasound that highlights the uveal
melanoma in patient no. 2.reports of practical oncology an
.  Introduction
lthough uveal melanoma is rare, it is the most common
rimary intraocular malignancy in adults, with an average
ncidence of 5.1 cases per million population. The median age
t diagnosis is 62 years, although the age at diagnosis can
ange from 6 to 100 years.1 Skin melanoma is an immuno-
enetic tumour frequently observed in patients whose normal
mmune response is suppressed, thus allowing cancer cells to
row.
Inflammatory bowel disease (IBD) is chronic multifacto-
ial disorder involving a complex interaction between genetic,
nvironmental, microbial, and innate and adaptive immune
actors. An inappropriate or excessive immune response
auses cytokine dysregulation and chronic inflammation. The
wo main types of IBD are Crohn’s disease (CD) and ulcera-
ive colitis (UC), which together have an overall prevalence of
pproximately 0.4% in both Europe and the United States.2
umerous studies have shown that IBD is associated with
n increased risk of developing non-melanoma skin cancer
NMSC).3–7
A comprehensive meta-analysis was performed of more
han 170,000 patients diagnosed with IBD to determine the
isk of melanoma in patients with IBD. They found 179 cases
f melanoma and calculated that patients with IBD had a 37%
igher risk of developing melanoma than expected in a gen-
ral population.8 Importantly, the patients in that sample who
ook immunomodulators had an even greater risk of develop-
ng skin melanoma.
To our knowledge, no previous reports have described
he correlation between IBD and uveal melanoma, although
amento et al. suggested a possible relationship between
rogression—but not onset—of uveal melanoma after tumour
ecrosis factor (TNF)—a inhibitor intake in a small case
eries.9 In the present case report, we  describe two young adult
ales diagnosed with IBD who  subsequently developed uveal
elanoma. We performed a literature review to examine a
ossible relationship between uveal melanoma and IBD.
.  Cases  description
.1.  Patient  1
.T.C. is a 28-year-old male diagnosed with rapidly-
rogressing UC at age 15. The disease was resistant to
oth corticosteroid and immunosuppressant treatment. After
wo years of treatment with monoclonal anti-TNF anti-
odies (Infliximab, Adalimumab), the patient underwent an
leostomy due to poor disease control. Since age 16, the patient
as been receiving treatment with Azathioprine 50 mg  twice
aily. He has no family history of melanoma. Twelve years
fter the diagnosis of UC, the patient developed ciliary body
elanoma in the right eye, measuring 15 mm × 11 mm,  with ahickness of 8.8 mm (Fig. 1). Chest-ray and abdominal ultra-
ound were performed to rule out metastasis. Treatment
onsisted of insertion of an iodine-125 COMS plaque around
he tumour to administer 75 Gy (0.84 Gy/h) to the tumour apex.Six months post-treatment, the patient is currently free of
disease.
2.2.  Patient  2
A.J.A. is a 24-year-old man  diagnosed with UC at age 20.
The patient received treatment with corticosteroids plus
Mesalazine for one year. Due to intolerance to Mesalazine,
treatment was switched to Azathioprine for the follow-
ing 3 years. Three years after the initial diagnosis of UC,
the patient developed a right choroidal melanoma measur-
ing 16 mm × 15 mm with a thickness of 8 mm (Fig. 2). No
metastatic lesions were detected. The patient’s family history
includes UC but no melanoma. After undergoing transscleral
surgical resection to remove the lesion, the patient under-
went adjuvant brachytherapy with iodine-125 COMS plaque
implant, receiving 75 Gy to the tumour bed. The patient has
recently (18 months after brachytherapy treatment) developed
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3.  Discussion
Both of these cases share several characteristics: young men
in their twenties with a long history of IBD, long-term
use of immunomodulatory drugs, and a diagnosis of uveal
melanoma in the third decade of life.
IBD is a well-known risk factor for skin melanoma. Indeed,
patients with IBD had a 37% higher risk of developing
melanoma than expected in the general population.8,10,11
However, the underlying mechanisms for developing skin
melanoma and NMSC in patients with IBD are not entirely
clear, although this increased risk in these patients could
be due to immune dysfunction resulting in altered tumour
surveillance and the use of immunomodulators.
Chronic inflammation can initiate tumours by directly
inducing DNA damage or by making cells more  susceptible
to mutagens.12–14
In addition, inflammation can act as a tumour promoter.
Inflammatory mediators—including cytokines such as TNF,
interleukin (IL)-1 and IL-6, growth factors, and chemokines,
as well as proteases produced by tumour-associated lympho-
cytes and macrophages—can enhance tumour cell growth by
promoting survival and proliferation of these cells. Tumour-
associated macrophages release inflammatory mediators that
stimulate tumour angiogenesis and lymphangiogenesis. The
immunomodulators used to treat IBD also play an important
role in tumour genesis.15–19
The association between TNF inhibitors and the risk
of developing melanoma has been the subject of intense
debate.20
A nested case-control study conducted by Long et al.
showed that the risk of melanoma was higher in patients
treated with biologics, but not with immunomodulators.21 An
analysis of the Food and Drug Administration Adverse Event
Reporting System carried out by McKenna et al.22 demon-
strated that TNF- inhibitor monotherapy or its concomitant
use with thiopurines in patients with IBD is associated with a
higher risk of developing melanoma and NMSC.
In the present report, we  describe two patients diagnosed
with IBD, both of whom were treated with immunomodu-
latory drugs. Both patients developed uveal melanoma—a
rare disease. Although previous publications have demon-
strated a correlation between IBD, immunomodulators, and
skin melanoma, this is the first report to describe a possible
correlation between IBD and uveal melanoma. We  hypothe-
size that the uveal melanoma in these two patients is related
to the IBD and the immunomodulatory treatments adminis-
tered. More  studies are warranted to investigate and confirm
this possible association.
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